A current overview of commercially available nucleic acid diagnostics approaches to detect and identify human gastroenteritis pathogens

Q1 Biochemistry, Genetics and Molecular Biology
Kate Reddington, Nina Tuite, Elizabeth Minogue, Thomas Barry
{"title":"A current overview of commercially available nucleic acid diagnostics approaches to detect and identify human gastroenteritis pathogens","authors":"Kate Reddington,&nbsp;Nina Tuite,&nbsp;Elizabeth Minogue,&nbsp;Thomas Barry","doi":"10.1016/j.bdq.2014.07.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose of review</h3><p>Gastroenteritis is caused by a wide range of viral, bacterial and parasitic pathogens and causes millions of deaths worldwide each year, particularly in infant populations in developing countries. Traditional microbiological culture and immunological based tests are time consuming, laborious and often lack diagnostic specificity and sensitivity. As a result patients can receive suboptimal and/or inappropriate antimicrobial treatment. In recent years, rapid nucleic acid diagnostics (NAD) technologies have become available to complement or even bypass and replace these traditional microbiological culture and immunological based tests.</p><p>The main purpose of this review is to describe a number of recently available multiparametric commercial tests, to support the rapid and accurate clinical diagnosis of human gastroenteritis. These state of the art technologies have the ability to identify a wide range of microorganisms associated with enteric gastroenteritis. Following further technological innovation and more comprehensive clinical validation studies, these NAD tests have the potential to impact on the economic burden of health care systems. These rapid NAD tests can also be used to guide improved patient therapy in a timely manner which will reduce the extent of morbidity and mortality associated with these infections globally.</p></div>","PeriodicalId":38073,"journal":{"name":"Biomolecular Detection and Quantification","volume":"1 1","pages":"Pages 3-7"},"PeriodicalIF":0.0000,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bdq.2014.07.001","citationCount":"52","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomolecular Detection and Quantification","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214753514000035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 52

Abstract

Purpose of review

Gastroenteritis is caused by a wide range of viral, bacterial and parasitic pathogens and causes millions of deaths worldwide each year, particularly in infant populations in developing countries. Traditional microbiological culture and immunological based tests are time consuming, laborious and often lack diagnostic specificity and sensitivity. As a result patients can receive suboptimal and/or inappropriate antimicrobial treatment. In recent years, rapid nucleic acid diagnostics (NAD) technologies have become available to complement or even bypass and replace these traditional microbiological culture and immunological based tests.

The main purpose of this review is to describe a number of recently available multiparametric commercial tests, to support the rapid and accurate clinical diagnosis of human gastroenteritis. These state of the art technologies have the ability to identify a wide range of microorganisms associated with enteric gastroenteritis. Following further technological innovation and more comprehensive clinical validation studies, these NAD tests have the potential to impact on the economic burden of health care systems. These rapid NAD tests can also be used to guide improved patient therapy in a timely manner which will reduce the extent of morbidity and mortality associated with these infections globally.

商业上可用的核酸诊断方法检测和鉴定人类肠胃炎病原体的当前概述
胃肠炎是由多种病毒、细菌和寄生虫病原体引起的,每年在全世界造成数百万人死亡,特别是在发展中国家的婴儿群体中。传统的微生物培养和免疫学检测费时费力,往往缺乏诊断特异性和敏感性。因此,患者可能接受次优和/或不适当的抗菌治疗。近年来,快速核酸诊断(NAD)技术已经可以补充甚至绕过和取代这些传统的微生物培养和免疫学检测。本综述的主要目的是描述一些最近可用的多参数商业测试,以支持快速准确的临床诊断人类肠胃炎。这些最先进的技术有能力识别与肠胃炎相关的各种微生物。随着进一步的技术创新和更全面的临床验证研究,这些NAD测试有可能对卫生保健系统的经济负担产生影响。这些快速NAD检测还可用于及时指导改进患者治疗,从而降低全球与这些感染相关的发病率和死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomolecular Detection and Quantification
Biomolecular Detection and Quantification Biochemistry, Genetics and Molecular Biology-Biochemistry
CiteScore
14.20
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信